{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Benning TJ"],"funding":["National Center for Advancing Translational Sciences","National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","National Institutes of Health","National Institute on Aging"],"pagination":["111026"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10872944"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["206"],"pubmed_abstract":["<h4>Aims</h4>To characterize glucagon fill rates and costs among youth with type 1 diabetes mellitus (T1DM).<h4>Methods</h4>Claims-based analysis of commercially-insured youth with T1DM included in OptumLabs® Data Warehouse between 2011 and 2021. Glucagon fill rates and costs were calculated overall and by formulation (injectable, intranasal, autoinjector, and pre-filled syringe). Sociodemographic and clinical factors associated with glucagon fills were examined using Cox regression.<h4>Results</h4>We identified 13,267 children with T1DM (76.4% non-Hispanic White). Over mean follow-up of 2.81 years (SD 2.62), 70.0% filled glucagon, with stable fill rates from 2011 to 2021. Intranasal glucagon had rapid uptake following initial approval, and it accounted for almost half (46.6%) of all gluca"],"journal":["Diabetes research and clinical practice"],"pubmed_title":["Glucagon fill rates and cost among children and adolescents with type 1 diabetes in the United States, 2011-2021."],"pmcid":["PMC10872944"],"funding_grant_id":["K23DK114497","K23 DK114497"],"pubmed_authors":["Benning TJ","McCoy RG","Al Nofal A","Herges JR","Heien HC","Creo AL"],"additional_accession":[]},"is_claimable":false,"name":"Glucagon fill rates and cost among children and adolescents with type 1 diabetes in the United States, 2011-2021.","description":"<h4>Aims</h4>To characterize glucagon fill rates and costs among youth with type 1 diabetes mellitus (T1DM).<h4>Methods</h4>Claims-based analysis of commercially-insured youth with T1DM included in OptumLabs® Data Warehouse between 2011 and 2021. Glucagon fill rates and costs were calculated overall and by formulation (injectable, intranasal, autoinjector, and pre-filled syringe). Sociodemographic and clinical factors associated with glucagon fills were examined using Cox regression.<h4>Results</h4>We identified 13,267 children with T1DM (76.4% non-Hispanic White). Over mean follow-up of 2.81 years (SD 2.62), 70.0% filled glucagon, with stable fill rates from 2011 to 2021. Intranasal glucagon had rapid uptake following initial approval, and it accounted for almost half (46.6%) of all gluca","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-04-04T01:18:24.877Z","creation":"2025-04-04T01:18:24.877Z"},"accession":"S-EPMC10872944","cross_references":{"pubmed":["38000667"],"doi":["10.1016/j.diabres.2023.111026"]}}